CN108371668A - 具有抗肿瘤作用的纳米羟基磷灰石粒子及制备方法和用途 - Google Patents
具有抗肿瘤作用的纳米羟基磷灰石粒子及制备方法和用途 Download PDFInfo
- Publication number
- CN108371668A CN108371668A CN201810157999.9A CN201810157999A CN108371668A CN 108371668 A CN108371668 A CN 108371668A CN 201810157999 A CN201810157999 A CN 201810157999A CN 108371668 A CN108371668 A CN 108371668A
- Authority
- CN
- China
- Prior art keywords
- nanometer hydroxyapatite
- particle
- average
- slurry
- crystallinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052588 hydroxylapatite Inorganic materials 0.000 title claims abstract description 86
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 title claims abstract description 85
- 239000002245 particle Substances 0.000 title claims abstract description 70
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000002002 slurry Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 238000005245 sintering Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 238000000498 ball milling Methods 0.000 claims description 15
- 238000001354 calcination Methods 0.000 claims description 11
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 10
- 239000012065 filter cake Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 8
- 238000001027 hydrothermal synthesis Methods 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 5
- 239000000908 ammonium hydroxide Substances 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000010335 hydrothermal treatment Methods 0.000 claims description 5
- 238000010334 sieve classification Methods 0.000 claims description 5
- VWDWKYIASSYTQR-YTBWXGASSA-N sodium;dioxido(oxo)azanium Chemical compound [Na+].[O-][15N+]([O-])=O VWDWKYIASSYTQR-YTBWXGASSA-N 0.000 claims description 5
- WHZWVUKPJBNTAK-UHFFFAOYSA-N hydroxy dihydrogen phosphite Chemical compound OOP(O)O WHZWVUKPJBNTAK-UHFFFAOYSA-N 0.000 claims description 4
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- FYHXNYLLNIKZMR-UHFFFAOYSA-N calcium;carbonic acid Chemical compound [Ca].OC(O)=O FYHXNYLLNIKZMR-UHFFFAOYSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 235000019738 Limestone Nutrition 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 238000010304 firing Methods 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000006028 limestone Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000009768 microwave sintering Methods 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 29
- 201000001441 melanoma Diseases 0.000 abstract description 16
- 210000004881 tumor cell Anatomy 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 11
- 230000035755 proliferation Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 238000003501 co-culture Methods 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 12
- 235000013339 cereals Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 230000031700 light absorption Effects 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241001330002 Bambuseae Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002097 psoas muscle Anatomy 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000253 induce tumour Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B25/00—Phosphorus; Compounds thereof
- C01B25/16—Oxyacids of phosphorus; Salts thereof
- C01B25/26—Phosphates
- C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/10—Particle morphology extending in one dimension, e.g. needle-like
- C01P2004/16—Nanowires or nanorods, i.e. solid nanofibres with two nearly equal dimensions between 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/51—Particles with a specific particle size distribution
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/54—Particles characterised by their aspect ratio, i.e. the ratio of sizes in the longest to the shortest dimension
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810157999.9A CN108371668B (zh) | 2018-02-25 | 2018-02-25 | 具有抗肿瘤作用的纳米羟基磷灰石粒子及制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810157999.9A CN108371668B (zh) | 2018-02-25 | 2018-02-25 | 具有抗肿瘤作用的纳米羟基磷灰石粒子及制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108371668A true CN108371668A (zh) | 2018-08-07 |
CN108371668B CN108371668B (zh) | 2020-11-24 |
Family
ID=63017985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810157999.9A Active CN108371668B (zh) | 2018-02-25 | 2018-02-25 | 具有抗肿瘤作用的纳米羟基磷灰石粒子及制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108371668B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109224123A (zh) * | 2018-10-11 | 2019-01-18 | 成都迪康中科生物医学材料有限公司 | 具有抑制肿瘤作用的纳米羟基磷灰石复合材料及制备方法 |
CN110496097A (zh) * | 2019-09-12 | 2019-11-26 | 四川大学 | 温控释放纳米羟基磷灰石的促组织修复生物可降解水凝胶 |
WO2020124495A1 (zh) * | 2018-12-20 | 2020-06-25 | 普惠德生技股份有限公司 | 含有亚铁氨基酸粒子的组合物及其用于制造治疗或改善胰脏相关疾病的医药品的用途 |
CN111643522A (zh) * | 2020-07-01 | 2020-09-11 | 四川大学华西医院 | 纳米羟基磷灰石在制备预防或治疗基底细胞癌的药物中的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101734635A (zh) * | 2009-12-31 | 2010-06-16 | 四川大学 | 一种纳米羟基磷灰石粉体的制备方法 |
CN103232233A (zh) * | 2013-04-26 | 2013-08-07 | 四川大学 | 由羟基磷灰石纳米棒或片构建的多孔纳米陶瓷及制备方法 |
CN104825490A (zh) * | 2015-04-23 | 2015-08-12 | 华东理工大学 | 具有抗肿瘤活性的羟基磷灰石纳米粒子及其制备方法和应用 |
-
2018
- 2018-02-25 CN CN201810157999.9A patent/CN108371668B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101734635A (zh) * | 2009-12-31 | 2010-06-16 | 四川大学 | 一种纳米羟基磷灰石粉体的制备方法 |
CN103232233A (zh) * | 2013-04-26 | 2013-08-07 | 四川大学 | 由羟基磷灰石纳米棒或片构建的多孔纳米陶瓷及制备方法 |
CN104825490A (zh) * | 2015-04-23 | 2015-08-12 | 华东理工大学 | 具有抗肿瘤活性的羟基磷灰石纳米粒子及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
汤薇: "羟基磷灰石纳米粒子抗肿瘤活性研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109224123A (zh) * | 2018-10-11 | 2019-01-18 | 成都迪康中科生物医学材料有限公司 | 具有抑制肿瘤作用的纳米羟基磷灰石复合材料及制备方法 |
CN109224123B (zh) * | 2018-10-11 | 2021-04-09 | 成都迪康中科生物医学材料有限公司 | 具有抑制肿瘤作用的纳米羟基磷灰石复合材料及制备方法 |
WO2020124495A1 (zh) * | 2018-12-20 | 2020-06-25 | 普惠德生技股份有限公司 | 含有亚铁氨基酸粒子的组合物及其用于制造治疗或改善胰脏相关疾病的医药品的用途 |
CN110496097A (zh) * | 2019-09-12 | 2019-11-26 | 四川大学 | 温控释放纳米羟基磷灰石的促组织修复生物可降解水凝胶 |
CN110496097B (zh) * | 2019-09-12 | 2021-06-01 | 四川大学 | 温控释放纳米羟基磷灰石的促组织修复生物可降解水凝胶 |
CN111643522A (zh) * | 2020-07-01 | 2020-09-11 | 四川大学华西医院 | 纳米羟基磷灰石在制备预防或治疗基底细胞癌的药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN108371668B (zh) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108371668A (zh) | 具有抗肿瘤作用的纳米羟基磷灰石粒子及制备方法和用途 | |
KR100807108B1 (ko) | 다공성의 β-인산삼칼슘 과립의 제조 방법 | |
CN103495209B (zh) | 自发荧光骨修复磁性缓释微球 | |
Gao et al. | Characterization and osteoblast-like cell compatibility of porous scaffolds: bovine hydroxyapatite and novel hydroxyapatite artificial bone | |
CN108498858B (zh) | 二硫化钼纳米片原位修饰生物陶瓷支架及其制备方法和应用 | |
Jenifer et al. | Investigation on antibacterial and hemolytic properties of magnesium-doped hydroxyapatite nanocomposite | |
CN113398327B (zh) | 一种高生物活性MXene/生物玻璃微球复合材料的制备方法 | |
Long et al. | Hierarchically nanostructured mesoporous carbonated hydroxyapatite microspheres for drug delivery systems with high drug-loading capacity | |
CN107158465B (zh) | 一种骨支架复合材料的制备方法 | |
CN113827767B (zh) | 一种用于骨瘤术后组织修复的新型微凝胶骨粉的制备方法 | |
Sukhodub et al. | Effect of magnetic particles adding into nanostructured hydroxyapatite–alginate composites for orthopedics | |
Aghajanian et al. | A 3D macroporous and magnetic Mg2SiO4-CuFe2O4 scaffold for bone tissue regeneration: Surface modification, in vitro and in vivo studies | |
CN108658102A (zh) | 一种提高磷酸镁骨水泥生物相容性的氧化镁原料及其制备方法 | |
US20210393848A1 (en) | Absorbable bone wax and preparation method thereof | |
CN114479123B (zh) | 一种锶掺纳米羟基磷灰石微球/壳聚糖水凝胶及制备方法 | |
CN112972767B (zh) | 一种具有促进成骨作用的磁响应组织工程材料及其制备方法与应用 | |
CN108864712B (zh) | 阴离子型两亲性短肽复合水凝胶、其制备方法及其应用 | |
CN114601969A (zh) | 含黑磷复合材料及其制备方法、应用 | |
CN112978695A (zh) | 一种高成骨活性仿生羟基磷灰石纳米粒子的制备方法 | |
CN111514372B (zh) | CaCO3/MgO纳米复合物及其在骨修复中的应用 | |
TWI769746B (zh) | 天然含鈣廢棄物製備之骨填補物及其製備方法 | |
CN112251225B (zh) | 一种绿色荧光白磷钙石纳米晶的制备方法 | |
CN109908405B (zh) | 一种多孔骨修复支架材料及其制备方法 | |
Bogoslovskaya et al. | Modern wound-healing gels with antibacterial properties based on copper nanoparticles | |
CN113384744B (zh) | 一种ws2纳米片/生物玻璃微球复合材料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20180807 Assignee: Sichuan baiamong bioactive materials Co.,Ltd. Assignor: SICHUAN University Contract record no.: X2021980005159 Denomination of invention: Nano hydroxyapatite particles with anti-tumor effect, preparation method and Application Granted publication date: 20201124 License type: Exclusive License Record date: 20210623 |
|
EM01 | Change of recordation of patent licensing contract | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20231123 Contract record no.: X2021980005159 License type after: Common License License type before: Exclusive License |